CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $192,626 | +168.1% | 6,477 | +62.5% | 0.01% | +166.7% |
| Q2 2023 | $71,846 | +12.2% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $64,031 | -19.3% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $79,341 | +1.7% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $78,000 | +5.4% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $74,000 | -5.1% | 3,987 | +11.9% | 0.00% | 0.0% |
| Q1 2022 | $78,000 | -22.8% | 3,562 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $101,000 | +68.3% | 3,562 | +24.5% | 0.00% | +50.0% |
| Q3 2021 | $60,000 | +11.1% | 2,860 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $54,000 | +45.9% | 2,860 | +19.7% | 0.00% | +100.0% |
| Q1 2021 | $37,000 | +8.8% | 2,390 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $34,000 | -8.1% | 2,390 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $37,000 | -11.9% | 2,390 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $42,000 | +200.0% | 2,390 | +151.1% | 0.00% | +100.0% |
| Q1 2020 | $14,000 | -41.7% | 952 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $24,000 | +71.4% | 952 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $14,000 | -41.7% | 952 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $24,000 | +84.6% | 952 | +65.9% | 0.00% | 0.0% |
| Q1 2019 | $13,000 | -23.5% | 574 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $17,000 | +6.2% | 574 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $16,000 | – | 574 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |